If the CCL2/CCR2 multi-protein signature were found to be predictive, DCIS patients absent for this protein signature would face a lower risk of progression and could potentially undergo fewer harsh treatments. The gene discussed is CCL2; the disease is ductal breast carcinoma in situ.